论著 Original Article

埃克替尼治疗37例晚期非小细胞肺癌疗效分析

Published at: 2016年第36卷第9期

朱礼阳 1 , 许春伟 2 , 于忠和 1
1 陆军总医院肿瘤科,北京 100700
2 军事医学科学院附属医院病理科,北京 100071
通讯作者 忠和 于 Email: 773080192@qq.com
DOI: 10.3978/j.issn.2095-6959.2016.09.019
基金:
国家自然科学基金 81372489
北京市科技计划课题 2131100006813032
军事医学科学院附属医院创新科研基金项目 ZH-2014-10

摘要

目的:探讨埃克替尼治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及毒副作用。方法:回顾性分析未行表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)治疗的晚期NSCLC患者37例,给予盐酸埃克替尼125 mg,3次/d,口服治疗,直到病变进展或不能耐受。随访12个月,评估疗效并观察药物毒副反应。结果:本组37例患者均可评价疗效,客观缓解率(objective response rate,ORR)为56.7%(21/37),疾病控制率(disease control rate,DCR)为84.6%(35/37),中位无进展生存期(median progression free survival,mPFS)为6个月(95%CI:5.27~6.74)。不良反应主要为皮疹和腹泻,多为Ⅰ、Ⅱ度,均可耐受。结论:盐酸埃克替尼治疗晚期肺腺癌安全、有效,不良反应可耐受。


Analysis of icotinib on treatment of 37 cases of advanced non-small cell lung cancer

Abstract

Objective: To evaluate the curative effect and safety of icotinib on treatment of advanced non-small cell lung cancer. Methods: 37 patients of advanced non-small cell lung cancer without treatment of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) were enrolled in the group. All the patients orally took icotinib 125 mg 3 times a day, until the disease progressed or the patients could not tolerate. Efficacy and drug toxicity was observed after 12 months followed-up. Results: Response could be assessed in all the 37 patients. The objective response rate (ORR) was 56.7% (21/37) and the disease control rate (DCR) was 84.6% (35/37). The main adverse reactions were rash and diarrhea, mostly degree Ⅰ or Ⅱ. Conclusion: Icotinib is an effective drug for the treatment of advanced non-small cell lung cancer, with an advantage of nice durability.


comments powered by Disqus

全文

引用

引用本文: 礼阳 朱, 春伟 许, 忠和 于. 埃克替尼治疗37例晚期非小细胞肺癌疗效分析[J]. 临床与病理杂志, 2016, 36(9): 1340-1344.
Cite this article as: ZHU Liyang, XU Chunwei, YU Zhonghe . Analysis of icotinib on treatment of 37 cases of advanced non-small cell lung cancer[J]. Journal of Clinical and Pathological Research, 2016, 36(9): 1340-1344.